Non-arteritic Ischemic Optic Neuropathy Clinical Trial
Official title:
A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
The study objectives are to assess any changes in visual acuity and visual field observed following the administration of RPh201 during an overall treatment period of at least 13 consecutive weeks with an option to extended the treatment phase to another 13 weeks (26 weeks total), and at the follow-up visit at 3 month after end of treatment in patients with optic nerve neuropathy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06031350 -
Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
|
||
Completed |
NCT03758118 -
Citicoline in Non-Arteritic Ischemic Optic Neuropathy
|
N/A | |
Recruiting |
NCT05305079 -
NA-AION Risk Factors: New Perspectives
|
||
Completed |
NCT01614158 -
Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy
|
N/A |